approval · primary record
MEPOLIZUMAB
FDA · BLA · 2025-05-22
| Agency | FDA |
|---|---|
| Submission type | BLA |
| Action date | 2025-05-22 |
| Brand | NUCALA |
| Sponsor | GLAXOSMITHKLINE LLC |
| Route | SUBCUTANEOUS LYOPHILIZED POWER |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-28T10:39:15.327Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: FDA:MEPOLIZUMAB:2025-05-22
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Mepolizumab · compound